NXL Nexalin Technology: Earnings per share for the last twelve months

Official company branding of Nexalin Technology, Inc. (NXL)

Nexalin Technology, Inc. (NXL) is developing HALO neurostimulation systems in collaboration with clinics to combat depression without medication. The measurement of annual EPS TTM growth visualizes profit dynamics, where the value 23.60 serves as the baseline indicator. However, slow physician adoption and regulatory barriers create risks, while liquidity shortages amid low sales force the company to rely on external capital.

NXL Nexalin Technology Inc: Earnings per share for the last twelve months in the range 02/11/2024 - 11/17/2026

Financial and market metric breakdowns for Nexalin (NXL)

- current quotes and average value forecast:
- company stock capitalization data:
Fundamental company valuation:NXL, Nexalin Technology Inc
Product sample of Nexalin Technology Inc

Analyzing the rolling year-over-year EPS chart allows for an assessment of the financial viability of Nexalin Technology, Inc. (NXL) given its high dependence on a single neurostimulation segment. This indicator calculates the daily ratio of current annual earnings per share to the previous year's, enabling investors to track value creation dynamics and business resilience as clinical trials expand in the US and China.